EUVIMEDEUVIMED entdecken
Crossref

Beyond the classics: The emerging value of anti-phosphatidylserine/prothrombin antibodies in antiphospholipid syndrome

Zetao Ding, Haoyu Pan, Zhixia Yang, Chengde Yang, Hui Shi

Clinical Immunology · 2023-11 · 256 · 109804

DOI: 10.1016/j.clim.2023.109804 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Immunology, 2023-11. Verfasst von Zetao Ding und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Thrombosis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 82 Literaturangaben. Gefördert von: Innovative Research Team of High-level Local University in Shanghai, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence of antiphospholipid antibodies (aPLs), which can lead to thrombosis and pregnancy complications. Within the diverse range of aPLs, anti-phosphatidylserine/prothrombin antibodies (aPS/PT) have gained significance in clinical practice. The detection of aPS/PT has proven valuable in identifying APS patients and stratifying their risk, especially when combined with other aPL tests like lupus anticoagulant (LA) and anti-β2-glycoprotein I (aβ2GPI). Multivariate analyses have confirmed aPS/PT as an independent risk factor for vascular thrombosis and obstetric complications, with its inclusion in the aPL score and the Global Anti-Phospholipid Syndrome Score (GAPSS) aiding in risk evaluation. However, challenges remain in the laboratory testing of aPS/PT, including the need for assay standardization and its lower sensitivity in certain patient populations. Further research is necessary to validate the clinical utility of aPS/PT antibodies in APS diagnosis, risk stratification, and management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiphospholipid SyndromeThrombosisFemalePregnancyHumansProthrombinPhosphatidylserinesAntibodies, Antiphospholipidbeta 2-Glycoprotein I

Stichwörter der Autor:innen

Anti-phosphatidylserine/prothrombin antibodyAntiphospholipid syndromeObstetric complicationsRisk stratificationThrombosis

Substanzen

ProthrombinPhosphatidylserinesAntibodies, Antiphospholipidbeta 2-Glycoprotein I

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Department of Rheumatology and Immunology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Electronic address: shihui_sjtu@sina.com.

Förderung

  • Innovative Research Team of High-level Local University in Shanghai
  • National Natural Science Foundation of China

Zitieren

APA

Ding, Z., Pan, H., Yang, Z., Yang, C., & Shi, H. (2023). Beyond the classics: The emerging value of anti-phosphatidylserine/prothrombin antibodies in antiphospholipid syndrome. Clinical Immunology, 256, 109804. https://doi.org/10.1016/j.clim.2023.109804

Vancouver

Ding Z, Pan H, Yang Z, Yang C, Shi H. Beyond the classics: The emerging value of anti-phosphatidylserine/prothrombin antibodies in antiphospholipid syndrome. Clinical Immunology. 2023;256:109804. doi:10.1016/j.clim.2023.109804

BibTeX
@article{Ding2023,
  author = {Ding, Zetao and Pan, Haoyu and Yang, Zhixia and Yang, Chengde and Shi, Hui},
  title = {Beyond the classics: The emerging value of anti-phosphatidylserine/prothrombin antibodies in antiphospholipid syndrome},
  journal = {Clinical Immunology},
  year = {2023},
  volume = {256},
  pages = {109804},
  doi = {10.1016/j.clim.2023.109804}
}
Kostenlos starten →